Cholinergic Neurons In Dementia With Lewy Bodies is a cell type relevant to neurodegenerative disease research. This page covers its role in brain function, involvement in disease processes, and significance for therapeutic strategies.
Dementia with Lewy bodies (DLB) is characterized by progressive cognitive decline, visual hallucinations, parkinsonism, and prominent cholinergic deficiency. Cholinergic neuron loss is a major contributor to the cognitive symptoms and is more severe than in Alzheimer's disease.
- Primary source: Cortical acetylcholine
- Neuronal loss: 50-70% in DLB
- Correlation: Cognitive impairment severity
- Brainstem cholinergic: Gait and attention
- Degeneration: Contributes to parkinsonism
- REM behavior disorder: Early manifestation
¶ Lewy Body Distribution
| Region |
Lewy Body Type |
Clinical Correlation |
| Cortex |
Cortical LB |
Visual hallucinations |
| Limbic |
Transitional LB |
Mood symptoms |
| Substantia nigra |
Brainstem LB |
Parkinsonism |
- Acetylcholine: 50-90% reduction in cortex
- ChAT activity: Markedly decreased
- Muscarinic receptors: Upregulated compensation
- Lewy body formation: Aggregated α-syn in neurons
- Synaptic dysfunction: Cholinergic transmission impairment
- Axonal transport: Disruption of BDNF trafficking
- Somatic mosaicism: Aging-related mutations
- Oxidative stress: Mitochondrial dysfunction
- Neuroinflammation: Microglial activation
- Attention deficits: Fluctuating alertness
- Executive dysfunction: Planning and reasoning
- Visuospatial impairment: Spatial orientation deficits
- Visual hallucinations: Early and prominent
- Depression: Anhedonia, apathy
- Delusions: Misidentification syndromes
- Cholinesterase inhibitors: Donepezil, rivastigmine
- Clinical benefit: Improved cognition and behavior
- Limitations: Does not modify disease progression
- α-Synuclein immunotherapy: Active and passive vaccination
- Neuroprotective agents: Neurotrophic factors
- Gene therapy: AAV-ChAT delivery
The study of Cholinergic Neurons In Dementia With Lewy Bodies has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Walker L, et al. Neuropathology of DLB. Acta Neuropathol. 2020;139(3):519-535.
- Ballard C, et al. Cholinergic dysfunction in DLB. Lancet Neurol. 2021;20(9):729-740.
- Outeiro TF, et al. Alpha-synuclein in DLB pathogenesis. Nat Rev Neurol. 2022;18(10):601-614.